Global regulators urge continuation of COVID-19 vaccine trials for longer-term safety and efficacy follow-up

EMA

27 November 2020 - EMA has endorsed a statement by the International Coalition of Medicines Regulatory Authorities that urges all stakeholders, including vaccines researchers and investigators, academia, regulators and the pharmaceutical industry, to continue COVID-19 vaccine trials beyond the time when the pre-defined cases of COVID-19 disease for final analysis in a trial have been reached. 

This can provide important additional and more precise information on longer-term safety and efficacy of a vaccine against COVID-19.

Read EMA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Europe , Vaccine , COVID-19